+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroparesis Drugs Market by Product Type, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Gastroparesis Drugs Market by Product Type, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Gastroparesis Drugs Market by Product Type, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924669
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gastroparesis Drugs Market grew from USD 4.54 billion in 2024 to USD 4.87 billion in 2025. It is expected to continue growing at a CAGR of 7.11%, reaching USD 6.85 billion by 2030.

Introduction to the Evolving Gastroparesis Therapeutics Landscape

The gastroparesis market is at a critical juncture, shaped by shifting patient needs, technological breakthroughs, and a dynamic regulatory environment. Patients suffering from delayed gastric emptying face limited therapeutic options and inconsistent efficacy, driving a demand for innovative solutions that can offer both symptomatic relief and long-term benefits. This report delivers a strategic lens on disease pathology, treatment paradigms, and emerging modalities, setting the stage for informed decision-making. By contextualizing the current landscape, we aim to equip stakeholders with the clarity needed to navigate market complexities, identify high-potential opportunities, and align investment priorities with clinical unmet needs.

Against a backdrop of escalating healthcare costs and heightened reimbursement scrutiny, the imperative for cost-effective yet clinically robust interventions has never been greater. This introduction frames the forthcoming analysis by highlighting the forces redefining drug development, market access challenges, and patient adherence dynamics. Ultimately, a nuanced understanding of these foundational elements will empower executives and innovators to chart a course toward sustainable growth and enhanced patient outcomes.

Emerging Forces Reshaping Gastroparesis Treatment Modalities

Innovations in molecular biology and digital health are redefining how gastroparesis is diagnosed, managed, and monitored. As real-world evidence becomes more accessible, precision dosing algorithms and wearable motility sensors are integrating into clinical workflows, enabling personalized treatment adjustments. Simultaneously, regulatory bodies are streamlining pathways for therapies targeting orphan diseases, opening avenues for both novel chemical entities and repurposed antibiotics to gain expedited approval.

In parallel, patient-centric care models are gaining traction. Telemedicine consultations and remote dosage titrations are reducing geographical barriers to specialist access, while telemetric gastric pacemakers are progressing through pivotal trials. Pharmaceutical manufacturers are also forging alliances with digital therapeutics firms to co-develop companion apps that track symptom severity and adherence in real time. These transformative shifts indicate a market in transition-from one defined by symptomatic management to an ecosystem where data-driven decision-making and combination regimens enhance clinical outcomes and economic value.

Implications of 2025 United States Tariff Adjustments on Drug Supply Chains

The introduction of targeted tariffs on active pharmaceutical ingredients and specialized manufacturing equipment is recalibrating cost structures across the supply chain. Raw materials sourced internationally are becoming subject to increased duties, prompting drugmakers to reassess sourcing strategies and renegotiate supplier contracts. This pressure is translating into elevated manufacturing overheads, which in turn affect pricing negotiations with payers and hospital systems.

To mitigate these tariff-induced headwinds, industry players are strategically diversifying production footprints, leveraging contract development and manufacturing organizations in tariff-free zones, and adopting lean manufacturing practices. Additionally, companies are accelerating procurement of long-lead items ahead of the tariff implementation date and exploring vertical integration for key intermediates. Through these adaptive measures, manufacturers aim to preserve margin integrity while maintaining supply continuity, ensuring patient access to essential gastroparesis therapies amid evolving trade policies.

Deep Dive into Segment Dynamics Driving Market Behavior

A granular examination of product types reveals divergent growth drivers for branded compounds versus generics, with brand owners prioritizing lifecycle management and generics specialists focusing on therapeutic equivalency and cost optimization. Within drug classes, dopamine antagonists such as Cisapride, Domperidone, and Metoclopramide remain foundational, yet motilin receptor agonists like Azithromycin and Erythromycin are carving out niche profiles based on prokinetic potency and safety. Furthermore, serotonin receptor agonists including Granisetron and Ondansetron are being repositioned to address overlapping symptom clusters beyond nausea control.

Route of administration exerts a profound influence on adoption dynamics, as injectable regimens enable rapid onset yet carry higher resource demands, whereas oral formulations offer convenience and home-care compatibility, and transdermal systems propose a non-invasive alternative that enhances patient adherence. Distribution channels from hospital pharmacies to online platforms and retail outlets shape access pathways, with digital storefronts accelerating direct-to-patient delivery models. Finally, understanding end-user environments-ranging from outpatient clinics to home care settings and acute hospital wards-allows innovators to tailor packaging, support services, and patient education programs with precision.

Regional Variations Informing Strategic Market Positioning

Regional landscapes exhibit distinct drivers based on healthcare infrastructure maturity, reimbursement frameworks, and disease prevalence patterns. In the Americas, robust clinical networks and high diagnostic awareness are fueling demand for next-generation prokinetics, while patient advocacy efforts are intensifying focus on quality-of-life endpoints. Europe, Middle East & Africa encompass a spectrum of markets-from centralized regulatory harmonization in the EU to capacity-constrained health systems in parts of Africa-necessitating agile market entry tactics and tiered pricing approaches.

Asia-Pacific presents heterogeneous opportunities: established markets such as Japan and Australia demonstrate strong uptake of advanced formulations, whereas emerging economies in Southeast Asia and India are characterized by volume-driven generics models and growing hospital investments in gastroenterology centers. Across all regions, public-private partnerships and regional clinical trials are strengthening local capabilities and expediting adoption of best practices, underscoring the importance of tailored go-to-market frameworks.

Competitive Benchmarks Spotlighting Leading Drugmakers

Leading pharmaceutical companies are consolidating expertise in prokinetic mechanisms through targeted R&D investments and strategic collaborations. Some market protagonists have launched patent-protected formulations of dopamine antagonists that claim improved receptor specificity to mitigate off-target effects. Others are expanding their pipeline portfolios by in-licensing motilin receptor agonists that demonstrate favorable pharmacokinetics and reduced QT prolongation risk.

In parallel, biotechnology firms are pioneering cell-based assays to screen novel small molecules, and advanced analytics vendors are supplying predictive modeling tools to optimize clinical trial design. Distribution partnerships between global drug manufacturers and regional pharmacy chains are cementing access, while cross-sector alliances with contract research organizations are expediting time-to-market for late-stage candidates. This convergence of capabilities is reshaping competitive positioning, compelling both established players and emerging entrants to articulate clear value propositions and investment rationales.

Strategic Imperatives for Industry Stakeholders

Decision-makers should prioritize a balanced portfolio that integrates patented and off-patent therapies to maximize market coverage. Investing in differentiated formulations, such as extended-release oral tablets or minimally invasive transdermal patches, can address adherence challenges while commanding premium pricing. Collaborative agreements with diagnostic technology providers will further strengthen patient stratification and optimize treatment algorithms.

Navigating tariff pressures requires establishing dual sourcing channels and securing long-term supply contracts to hedge against cost volatility. Companies are advised to explore strategic partnerships in tariff-neutral jurisdictions to insulate manufacturing pipelines. Expanding presence in underpenetrated regions through licensing agreements or joint ventures can capture volume opportunities while mitigating regulatory risk. Finally, embedding digital health components into product offerings will enhance patient engagement, facilitate outcomes tracking, and unlock new reimbursement pathways.

Robust Methodological Framework Guiding Our Analysis

This study employs a multi-layered research framework combining exhaustive secondary research with structured primary engagements. Initially, public disclosures, peer-reviewed journals, patent landscapes, regulatory filings, and industry white papers were systematically reviewed to establish foundational insights. Subsequently, over 30 in-depth interviews with clinicians, key opinion leaders, supply-chain experts, and patient advocacy group representatives were conducted to validate secondary findings and uncover nuanced perspectives.

Analytical rigor was applied through data triangulation techniques, ensuring consistency across diverse information sources. Competitive landscape mapping leveraged proprietary databases to track product pipelines, M&A activities, and alliance formations. Qualitative insights were quantified via structured scoring models to assess factors such as clinical differentiation, market readiness, and reimbursement potential. Quality assurance protocols, including editorial reviews and methodological audits, guarantee the integrity and reliability of the conclusions presented herein.

Synthesizing Insights to Navigate Future Opportunities

In summary, the gastroparesis drug market is poised for significant evolution driven by technological integration, strategic realignments, and regulatory recalibrations. Stakeholders who marry clinical innovation with agile supply-chain strategies and tailored market approaches will be best positioned to capture emergent growth pockets. By synthesizing competitive benchmarks, segmentation dynamics, and regional nuances, this report illuminates pathways to sustainable profitability and improved patient care.

Looking ahead, continuous monitoring of trade policies, therapeutic advances, and patient feedback loops will be essential to refine product portfolios and commercial tactics. The insights provided serve as a compass for executives and investors seeking to navigate the complexities of this rapidly changing landscape, empowering them to make data-driven decisions that align with both business objectives and patient needs.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Branded
    • Generics
  • Drug Class
    • Dopamine Antagonists
      • Cisapride
      • Domperidone
      • Metoclopramide
    • Motilin Receptor Agonists
      • Azithromycin
      • Erythromycin
    • Serotonin Receptor Agonists
      • Granisetron
      • Ondansetron
  • Route Of Administration
    • Injectable
    • Oral
    • Transdermal
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • AbbVie Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Motus GI Holdings, Inc.
  • Pfizer Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gastroparesis Drugs Market, by Product Type
8.1. Introduction
8.2. Branded
8.3. Generics
9. Gastroparesis Drugs Market, by Drug Class
9.1. Introduction
9.2. Dopamine Antagonists
9.2.1. Cisapride
9.2.2. Domperidone
9.2.3. Metoclopramide
9.3. Motilin Receptor Agonists
9.3.1. Azithromycin
9.3.2. Erythromycin
9.4. Serotonin Receptor Agonists
9.4.1. Granisetron
9.4.2. Ondansetron
10. Gastroparesis Drugs Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Transdermal
11. Gastroparesis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Gastroparesis Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
13. Americas Gastroparesis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gastroparesis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gastroparesis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd.
16.3.2. Viatris Inc.
16.3.3. Sandoz International GmbH
16.3.4. Sun Pharmaceutical Industries Ltd.
16.3.5. Dr. Reddy's Laboratories Ltd.
16.3.6. Johnson & Johnson
16.3.7. AbbVie Inc.
16.3.8. Ironwood Pharmaceuticals, Inc.
16.3.9. Motus GI Holdings, Inc.
16.3.10. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GASTROPARESIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. GASTROPARESIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 57. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 58. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 129. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 130. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 131. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 185. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 186. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 187. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 249. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 250. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 251. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 274. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 275. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 276. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 282. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 283. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 284. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 322. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 323. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 324. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES GASTROPARESIS DRUGS MA

Companies Mentioned

The companies profiled in this Gastroparesis Drugs market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • AbbVie Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Motus GI Holdings, Inc.
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.85 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Diabetic Gastroparesis (DGp) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Diabetic Gastroparesis (DGp) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Gastroparesis Drugs Market Report 2025 - Product Image

Gastroparesis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gastroparesis Drugs Market 2025-2029 - Product Image

Gastroparesis Drugs Market 2025-2029

  • Report
  • 198 Pages
  • Global
From

About the Gastroparesis Drug Market

Gastroparesis Drug is a type of drug used to treat gastroparesis, a condition in which the stomach muscles are weakened and unable to properly move food through the digestive system. These drugs are used to reduce symptoms such as nausea, vomiting, bloating, and abdominal pain. Commonly prescribed drugs for gastroparesis include metoclopramide, domperidone, and erythromycin. Other drugs, such as prokinetics, may also be used to help improve gastric emptying. Gastroparesis Drug is a part of the larger Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal conditions. These drugs are used to reduce symptoms, improve digestion, and prevent further complications. Commonly prescribed drugs in this market include antacids, proton pump inhibitors, and laxatives. Some companies in the Gastroparesis Drug market include Novartis, GlaxoSmithKline, Pfizer, and Takeda. Other companies, such as Allergan, Merck, and AstraZeneca, also produce drugs for the treatment of gastroparesis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.